In recent years, several small-molecule inhibitors targeting FGFR4 for the treatment of HCC and other solid tumors harboring aberrant FGFR4 signaling have entered clinical trials [7, 8]. This evidence concerns the gene FGFR4 and hepatocellular carcinoma.